huntington

Is there a reference bibliography that helps in the management of the patient?

Good morning, I'm a psychotherapist with cognitive-behavioral orientation.
Recently, I was assigned a task in an integrated facility, with guests mainly suffering from Alzheimer's disease, senile dementia and oligophrenia. Average age 75 years.
Together with these guests there is a 54 year old boy with Huntington’s Disease. He was an accountant. Unfortunately, there is no medical record with the history of the patient. The operators told me that he had a sister (the one who then took him to the facility and that unfortunately I have not yet had the pleasure of meeting to interview in person) and that no one in the family had suffered from this disease. I read the last certificate dating back to 2015 made by the neurology department of a Local Health Unit (ASL) in Sardinia, stating that the patient had not substantially worsened.
Well, I did not know this disease but I immediately thought that in the facility, the boy, at this time, had "more need".
The stage of the disease, I think, is advanced. The patient is always seated in the wheelchair, contained with the belt on the front. He has difficulties in expressing himself (and I can understand that... because I don't know whether to attribute his gestures to the disease or to a request for something). He often understands what I ask him if expressed in a simple way. I have noticed that he gets very nervous when he hears the noise made by other patients and when he is hungry (he eats quite voraciously). As I mentioned earlier, not knowing the disease in depth, I documented myself but I notice that there is information regarding the disease but not a bibliography that could be useful from the practical side. I thank you in advance for taking the time to answer to me.

4 Dicembre 2017 - Con il Premio, quest'anno alla sua I Edizione, la Fondazione intende valorizzare i ricercatori italiani che svolgono le migliori ricerche, cliniche o biologiche applicate, pubblicate o in corso di pubblicazione, su riviste scientifiche indicizzate. 

An important study has led to the development of a cognitive assessment tool that could help predict the severity of Huntington disease (HD) in those close to onset.

Huntington disease (HD) - a condition that affects one’s movement, cognition, and behavior—manifests fully in adulthood.

PTC518 is a small molecule capable of reducing the protein that causes Huntington's disease.

Pivot-HD: new hope for the treatment of Huntington Disease

PTC518 is a small molecule capable of reducing the protein that causes Huntington's disease (HD).

The appointment is at the Antas Theater in San Sperate (Cagliari) at 3.00 pm, Saturday 28 May 2022.

In the HD Awareness Month, LIRH Sardinia Association promotes a meeting open to Huntington families, to share spaces and times, thoughts, needs and information on the current available therapeutic options and on the disease management.

"Sardinian families have been isolated for too long." - said Alessia Zurru, President of the LIRH Sardinia Association - The time has come, also for us, to be taken in charge and to access experimental programs ".

Last Saturday, March 19, 2022, on the initiative of a group of patients and family members willing to advocate for their right to treatment, the Italian Huntington Research League (LIRH) Sardinia was officially born.

We are happy to announce that last Saturday, March 19, 2022, on the initiative of a group of patients and family members willing to advocate for their right to treatment, the Italian League Huntington Research Association (LIRH) Sardinia was officially born.

uniQure announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.

On the last February 2, 2022 uniQure sent out a press release with new updates on their gene therapy for Huntignton Disease.

Pharmaceutical companies confront researchers and patients on the HD treatments perspectives

The future of therapeutic research to cure Huntington's disease.

This is the title of the LIRH Foundation 2021 Annual Conference, which will take place online next Friday 3 December, from 15.00 to 17.30 CET.

Giorgia has offered to make her positive yoga experience available to other people living in contact with Huntington's disease.

 

Giorgia has offered to make her positive yoga experience available to other people living in contact with Huntington's disease. We have collected his testimony: